Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma

The independent data monitoring committee (IDMC) has recommended continuation of CLINGLIO without modification after its assessment of LAM561 interim efficacy in newly diagnosed Glioblastoma. This follows the previous recommendation in relation to safety. CLINGLIO remains on track to have its open readout at 66 progression events, expected in summer 2024.

PALMA DE MALLORCA, Spain, March 5, 2024 /CNW/ -- Laminar Pharmaceuticals S.A., a clinical-stage biotechnological company developing novel therapies to treat diverse pathologies with unmet clinical needs, is pleased to announce that the Independent Data Monitoring Committee (IDMC) after evaluating the interim clinical results of the CLINGLIO clinical trial, has recommended that the trial should "continue without modifications." The CLINGLIO study is a multinational, phase 2b/3, randomized, double-blind clinical trial evaluating LAM561 in combination with standard-of-care (SoC; combined tumour resection and chemoradiotherapy) for newly diagnosed glioblastoma (GBM) patients. The CLINGLIO trial, funded by a European Commission Grant (H2020) is being carried out in 21 hospitals in Spain, Italy, France, and UK. The investigational study drug, LAM561 (idroxioleic acid, sodium; 2-OHOA) is a synthetic fatty acid with a novel therapeutic approach, administrated orally to treat this devastating type of cancer.

As part of the pre-specified plan, the experts from the IDMC committee at their meeting on February 23 recommended, based upon their evaluation of the unblinded medical and clinical statistical data from 103 patients, that the CLINGLIO trial should continue without modification. This interim analysis was conducted following the committee's assessment of the efficacy – survival without progression (tumor growth or clinical deterioration) – of LAM561 after 45 progression events have occurred. This recommendation was eagerly awaited by Laminar as it ensures that the trial remains on track to have its first open readout at 66 progressions, expected in the Summer of 2024. Moreover, this interim recommendation by the IDMC confirms that with the current level of evidence, futility (lack of clinical benefit of the drug) has not been identified and continuance of the study is recommended.

"The positive IDMC interim review of LAM561 efficacy in newly diagnosed GBM represents a leap forward for our most advanced development. This is the first time that the efficacy of LAM561 has been assessed against placebo, a huge milestone in the project, and this recommendation was the best possible outcome at this stage," said Dr Pablo Escribá, Chief Executive Officer of Laminar Pharmaceuticals. "With the IDMC's recommendation, we will continue to advance the CLINGLIO study to confirm the potential of LAM561 to improve the prognosis and quality of life in first-line glioblastoma patients treated with standard-of-care."

From Laminar's point of view, this positive and expected recommendation follows the encouraging results from previous IDMC meeting, focused on safety, held in September 2023, in which no concerns were raised based on evaluation of the available safety data. Subsequent ongoing follow-up and monitoring of medical and pharmacovigilance data have not raised any further safety concerns to the medical team and study monitor nor the trial's Ethics Board. Oral LAM561 has been well tolerated and indicates a safety profile consistent with prior clinical trials.

"A leap forward, and also the beginning of the last step to potentially reach clinical practice, as the next planned interim analysis will provide the unblinded clinical benefit/risk ratio data needed for the request for Conditional Market Authorization," – added Dr Adrian G. McNicholl, Laminar's Chief of Clinical Operations. "However, even though we are hopeful with the advancement of the LAM561 clinical program, we must be careful not to raise patient's expectations, as this is an investigational medicinal product, and we need to wait until the outcome of the next interim analysis has been re-evaluated by the IDMC and has been assessed by the regulatory agencies with whom we are already in direct contact."

As a designated orphan medicinal product in the EU, the study protocol, scientific validity, methodology, analyses and endpoints have been discussed in detail with the EMA during successive requests for Protocol Assistance. The CLINGLIO trial is considered pivotal in that results showing significant clinical benefit could be sufficient for a request for conditional marketing authorization in the EU late this year; and potential full marketing authorization in 2025, for which enabling pre-submission interactions with the EMA have been initiated.

About Laminar Pharmaceuticals S.A.

Laminar Pharmaceuticals S.A. (Laminar) is a Spanish biotechnological company created in 2006, committed to translational health research, for the rational design and development of drugs to treat oncological and other pathologies in the form of synthetic fatty acids considered "First-in-class Health Solutions" and based on a novel technology, the Melitherapy (MLT or Membrane Lipid Therapy). Laminar controls all the processes, from the rational design of the molecules to the clinical trials that lead up to the launch of a new drug, with constant investment in R&D and high-quality standards. It is currently headquartered in Mallorca (Spain) with a subsidiary in Massachusetts (USA).

About Glioblastoma

Glioblastoma (GBM) is the most common primary malignant brain tumor and accounts for nearly 50 percent of all gliomas and approximately 25 percent of all primary brain and CNS malignant tumors. The incidence of GBM in Europe is currently above 25,000 new cases each year, rising to over 100,000 cases per year worldwide. The prognosis for GBM patients is very poor, with a median survival time of about 14.5 months despite optimum chemo-radiation treatment. About 15% of patients survive two years after diagnosis and ca. 4% survive for five or more years. In this scenario, there is a desperate need for novel treatment alternatives that provide safe and more efficacious clinical outcomes.

About LAM561

LAM561 (2-hydroxyoleic acid (2-OHOA); idroxioleic acid, sodium) is a synthetic derivative of oleic acid and the most advanced R&D product which is taken orally. This drug alters the composition of the plasma membrane in cancer cells, reducing the activity of membrane-associated signaling proteins that are known to promote tumor growth and affecting tumours in the brain. LAM561 is in the process of completing its last clinical development phase and has shown promising preliminary clinical activity in the treatment of aggressive brain tumors, glioblastoma.

Media Contact:
Javier Fernández Díaz
[email protected]

SOURCE Laminar Pharmaceuticals, S.A.